Beyond Suppression: The Next Wave of HIV Treatment
For decades, oral antiretroviral therapy (ART) has transformed HIV from a death sentence into a manageable chronic condition. Now, a novel era is dawning, driven by long-acting injectables and a deeper understanding of the immune system’s potential to not just suppress, but potentially conquer, the virus. While injectables offer logistical improvements – reducing clinic visits and simplifying adherence – the ultimate goal extends beyond simply controlling viral load.
The Limits of Viral Suppression
Long-acting injectables, like cabotegravir and rilpivirine, represent a significant advancement, particularly for individuals facing challenges with daily pill adherence. However, like their oral counterparts, these injectables don’t eliminate the virus entirely. HIV establishes latent reservoirs of infected cells, remaining hidden from both ART and the immune system. This means treatment must be lifelong, and any interruption in the supply chain can lead to viral rebound and potential drug resistance.1,2
even with viral suppression, people living with HIV face an increased risk of comorbidities like cancer, cardiovascular disease, and neurocognitive disorders.3,4 This highlights the necessitate for therapies that address the underlying immune dysfunction, not just the virus itself.
Harnessing the Immune System: A New Approach
The focus is shifting towards therapeutic strategies that empower the immune system to eliminate and recover from HIV infection. A universally effective prophylactic vaccine remains a primary goal, but HIV’s remarkable ability to evade the immune system presents a formidable challenge. Unlike many other viruses, Notice no known cases of natural sterilizing immunity to HIV.5
The Promise of Broadly Neutralizing Antibodies
One promising avenue involves harnessing the power of broadly neutralizing antibodies (bnAbs). These antibodies can target conserved regions of the HIV protein, offering protection against diverse viral strains. However, naturally occurring bnAbs develop slowly, often only after years of chronic infection. Researchers are exploring ways to accelerate this process.
Strategies include stepwise vaccination using mRNA platforms to activate rare precursor B cells, followed by a booster to guide the immune system towards bnAb production.7 Direct infusion of long-acting bnAbs and gene-editing approaches to induce bnAb production are also under investigation.7
Eliminating Viral Reservoirs: The Path to a Cure
Latent viral reservoirs pose a major obstacle to a cure. Researchers are developing latency-reversing agents (LRAs) designed to “shock” these reservoirs, making infected cells visible to the immune system. Chromatin remodelers, which alter the structure of DNA within infected cells, are one class of LRAs being explored.9
The strategy involves “waking up” the virus with LRAs, then suppressing it with ART and bolstering the immune response with therapeutic vaccines and bnAbs. Multiple clinical trials combining these approaches are currently underway.9,10
Pediatric HIV: A Unique Opportunity
Newborns at risk of HIV infection represent a particularly promising population for these novel therapies. The well-defined at-risk group and the potential to avoid lifelong ART dependence make this a compelling area of research. The pediatric immune system may also be more receptive to inducing bnAb production.11,12 Several ongoing trials are focused on inducing immunity against HIV in children, including the AbVax trial.13
Gene Editing: A High-Tech Approach
Gene editing technologies, such as CRISPR/Cas9, offer another potential path to HIV resistance. The goal is to disrupt the genes that HIV uses to enter cells (CCR5 and CXCR4) or to directly excise the viral DNA from the host genome.9 While promising in preclinical studies, challenges remain in achieving efficient delivery, minimizing off-target effects, and ensuring long-term engraftment.14
Will These Advances Reach Everyone?
Developing these next-generation therapies is complex and costly. While a vaccine offering broad, population-wide protection may remain elusive, these advances could provide alternative prevention and treatment options for high-risk populations.15
The key will be ensuring that these therapies are accessible, affordable, and deployable in resource-limited settings. The success of long-acting injectables demonstrates the value of addressing logistical barriers to care. Future therapeutic developers should prioritize populations underserved by current ART-based interventions and focus on improving outcomes for those most in need.15
Did you understand?
The development of long-acting injectables was informed by decades of research into HIV immunology, even research that didn’t directly lead to a vaccine. These incremental advances have paved the way for the progress we see today.
Frequently Asked Questions
- What are long-acting injectables? They are HIV medications delivered via injection, reducing the need for daily pills.
- Can HIV be cured? Currently, there is no widely available cure for HIV, but research is ongoing to find one.
- What are broadly neutralizing antibodies? These are antibodies that can target multiple strains of HIV, offering broad protection.
- What are latency-reversing agents? These are drugs designed to “wake up” hidden HIV reservoirs, making them vulnerable to treatment.
Explore more: HIV/AIDS Treatment Guidelines
